

Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.

FOR IMMEDIATE RELEASE, September 26, 2001

Immunex Corporation Appoints Laura Hamill to Vice President, Marketing for ENBREL® (etanercept)

SEATTLE -Immunex Corporation (NASDAQ: IMNX) today announced that Laura Hamill has been promoted to vice president of marketing for ENBREL® (etanercept). A seasoned pharmaceutical marketing executive, Ms. Hamill will be responsible for overseeing initiatives in existing and potential new markets for ENBREL.

"Laura's extensive experience in marketing and advertising have greatly contributed to the strong branding of ENBREL," said Barry Labinger, senior vice president and general manager, commercial operations at the company. "Her leadership will continue to drive new initiatives for this innovative product as we look toward potential additional markets."

Prior to joining Immunex last year, Hamill was executive vice president at Klemtner Advertising in New York where she oversaw advertising and marketing programs for a number of brands including ENBREL. She previously worked at Hoffmann La-Roche Laboratories for seven years in sales, market research and product management positions. She holds a Bachelor's degree in Marketing from the University of Arizona.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.